The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males
Status:
Completed
Trial end date:
2020-11-11
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the effect of the moderate cytochrome
P450 3A (CYP3A) inducer rifabutin on the pharmacokinetics (PK) of zanubrutinib in healthy
males.